AbbVie
Bookmark
ShareCopied to clipboardAbbVie is a company. It is a public company in North Chicago, the United States. It was founded in 2013 and its current CEO is Elizabeth Shea. It is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: North Chicago
- country: United States
- employees: 55,000 people
- revenues: 56.3B $
- company type: public
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 2013
- CEO: Elizabeth Shea
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about AbbVie:
Dataset of stocks from AbbVie:
AbbVie is one of the companies in the United States, companies in Pharmaceuticals, companies in Health Care, companies in North Chicago and 3,456,808 companies in our database.
Talking Points
- Pharmaceutical Research & Development
- AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
- AbbVie's global handle featuring biopharmaceutical news & updates managed by our corp digital team. Review our guidelines: https://t.co/1jp5yBkNx7
- AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition ...
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- AbbVie News CenterNews
- We use advanced science, expertise & passion to solve serious health issues & have a remarkable impact on people's lives | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key ...
- Difference makers wanted
- Explore our career opportunities.
- News Center | AbbVie News Center
- AbbVie Inc. Newsroom - the official site for press releases, photos, video, audio, pr contact information, presskits and more.
- In July 2015, Naurex Inc. entered into a definitive agreement to be acquired by Allergan plc. The transaction was successfully closed in August 2015. For more information, please visit...
- Allergan is now part of AbbVie
- We discover and develop innovative medicines for tomorrow, while helping people live better lives today.
- Allergan is now part of AbbVie. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health ...
- AbbVie Completes Acquisition of Landos Biopharma
- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH...